Pirarubicin

Pirarubicin

SCHEMBL8324

COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)CC3O[C@H]1C[C@H](N)[C@H](O[C@@H]2CCCCO2)[C@H](C)O1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 1.00
KMT2A Q03164 8/20 1.00
BLM P54132 7/20 1.00
PTGS1 P23219 3/20 1.00
HTT P42858 3/20 1.00
HDAC6 Q9UBN7 2/20 1.00
ECE1 P42892 1/20 1.00
MUS81 Q96NY9 1/20 1.00
THRB P10828 7/20 0.79
RECQL P46063 6/20 0.79
HIF1A Q16665 6/20 0.79
SMN1; SMN2 Q16637 6/20 0.79
BRCA1 P38398 6/20 0.79
TOP2A P11388 5/20 0.79
TDP1 Q9NUW8 5/20 0.79
MAPT P10636 5/20 0.79
MAPK1 P28482 4/20 0.79
STAT6 P42226 4/20 0.79
CHRM1 P11229 3/20 0.79
TBXA2R P21731 3/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pirarubicin SCHEMBL31499425 1.00 MEN1 (1.00) MEN1KMT2ABLMPTGS1HTT
Pirarubicin SCHEMBL13421276 1.00 MEN1 (1.00) MEN1KMT2ABLMPTGS1HTT
Pirarubicin SCHEMBL8323 1.00 MEN1 (1.00) MEN1KMT2ABLMPTGS1HTT
Pirarubicin SCHEMBL29363840 1.00 MEN1 (1.00) MEN1KMT2ABLMPTGS1HTT
Pirarubicin SCHEMBL12257450 1.00 MEN1 (1.00) MEN1KMT2ABLMPTGS1HTT
Pirarubicin SCHEMBL15472856 1.00 MEN1 (1.00) MEN1KMT2ABLMPTGS1HTT
Pirarubicin SCHEMBL12202618 1.00 MEN1 (1.00) MEN1KMT2ABLMPTGS1HTT
Pirarubicin SCHEMBL6314144 1.00 MEN1 (1.00) MEN1KMT2ABLMPTGS1HTT
Pirarubicin SCHEMBL31238420 0.99 MEN1 (0.99) MEN1KMT2ABLMPTGS1HTT
Pirarubicin SCHEMBL99651 0.99 MEN1 (0.99) MEN1KMT2ABLMPTGS1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 51593 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4748859-A2 CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF The Regents of the University of California (US) 2026-05-27 EP claimed
US-20260137794-A1 LIGAND-DRUG CONJUGATE AND USE THEREOF SYSTIMMUNE INC (US) 2026-05-21 US claimed
EP-4743490-A1 HUMANIZED ANTI-CD7 ANTIBODY Christian-Albrechts-Universität zu Kiel (DE) 2026-05-20 EP claimed
EP-4744680-A1 TARGETED CHEMICAL DRUG AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE OF TARGETED CHEMICAL DRUG Bai Yao Zhi Da (Beijing) Nanobio Technology Co., Ltd. (CN) 2026-05-20 EP claimed
CN-122056884-A Methods of treating pancreatic cancer 坎莫森特里克斯公司 2026-05-19 CN claimed
WO-2026099502-A1 NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 2026-05-15 WO claimed
EP-4737898-A2 SEPARATION AND ISOLATION OF NUCLEIC ACIDS USING AFFINITY LIGANDS BOUND TO A SOLID SURFACE EMP Biotech GmbH (DE) 2026-05-06 EP claimed
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
EP-4727589-A1 PROTAMINE-COATED NUCLEIC ACID/THERAPEUTIC AGENT COMPLEXES, AND USES THEREOF The Regents of the University of California (US) 2026-04-22 EP claimed
WO-1999001118-A9 ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS ATHEROGENICS INC (US) 1999-05-20 WO claimed
US-5874412-A ANTICANCER AGENTS PRIEBE WALDEMAR (US) 1999-02-23 US claimed
WO-1999001118-A2 ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS ATHEROGENICS, INC. (US) 1999-01-14 WO claimed
WO-1998032718-A1 NEW FATTY ACID DERIVATIVES NORSK HYDRO ASA (NO) 1998-07-30 WO claimed
CN-1165518-A Novel anthracycline derivatives and pharmaceutical preparations thereof JAPAN SCIONCE AND TECHNOLOGY C (JP) 1997-11-19 CN claimed
WO-1997034612-A1 BIS-ANTHRACYCLINES WITH HIGH ACTIVITY AGAINST DOXORUBICIN RESISTANT TUMORS PRIEBE WALDEMAR (US) 1997-09-25 WO claimed
EP-0795561-A1 NOVEL ANTHRACYCLINE COMPOUND DERIVATIVES AND MEDICINAL PREPARATIONS CONTAINING THE SAME Japan Science and Technology Corporation (JP) 1997-09-17 EP claimed
EP-0393575-B1 Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent SEARLE & CO (US) 1994-03-16 EP claimed
WO-1993005774-A1 COMPLEXES OF ANTHRACYCLINE ANTIBIOTICS WITH POLYUNSATURATED FATTY ACIDS IN LIPID EMULSIONS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 1993-04-01 WO claimed
EP-0393575-A1 Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent G.D. Searle & Co. (US) 1990-10-24 EP claimed